Skip to main content

Advertisement

SpringerLink
Log in

Androgen Receptor Increases CD133 Expression and Progenitor-Like Population That Associate With Cisplatin Resistance in Endometrial Cancer Cell Line

  • Original Article
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Endometrial cancer (EMC) is a sex steroid hormone-related female malignancy. Androgen and androgen receptor (androgen/AR) signals have been implicated in EMC progression. Cancer stem/progenitor cells (CSPCs) are suspected to link to chemoresistance in patients with EMC. In this study, we examined the androgen/AR roles in cisplatin resistance and CSPC population. We found AR expression increased naive EMC side population, CSPC population, cell migration, and epithelial-mesenchymal transition. Meanwhile, it decreased cisplatin cytotoxic effect on EMC cells. Collaterally, endogenous AR expressions in EMC cells were upregulated in the cisplatin-resisting state. Moreover, AR expression could further enhance CD133 expression, CSPC-related markers, and drug-resistance gene messenger RNA expression in EMC cells. Finally, the AR-associated gene expression might go through indirect regulation. This is the first report revealing AR function on EMC cells’ CSPC and cisplatin resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.

    Google Scholar 

  2. Arora V, Quinn MA. Endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2012;26(3):311–324.

    Article  PubMed  Google Scholar 

  3. Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. Lancet. 2012; 379(9823): 1352–1360.

    Article  PubMed  Google Scholar 

  4. Pierga JY, Dieras V, Paraiso D, Pouillart P. Chemotherapy of metastatic endometrial carcinoma. Review of the literature. Bull Cancer. 1995;82(12):1005–1018.

    CAS  PubMed  Google Scholar 

  5. Vermorken JB, Hoekman K. Chemotherapy for gynecologic malignancies. Curr Opin Oncol. 1995;7(5):457–465.

    Article  CAS  PubMed  Google Scholar 

  6. Nakamura M, Kyo S, Zhang B, et al. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol. 2010;41(11):1516–1529.

    Article  CAS  PubMed  Google Scholar 

  7. Rutella S, Bonanno G, Procoli A, et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res. 2009;15(13):4299–4311.

    Article  CAS  PubMed  Google Scholar 

  8. Rahadiani N, Ikeda J, Mamat S, et al. Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Sci. 2011;102(4):903–908.

    Article  CAS  PubMed  Google Scholar 

  9. Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science. 1988;240(4850):324–326.

    Article  CAS  PubMed  Google Scholar 

  10. Yeh S, Tsai MY, Xu Q, et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA. 2002;99(21):13498–13503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hu YC, Wang PH, Yeh S, et al. Subfertility and defective follicu-logenesis in female mice lacking androgen receptor. Proc Natl Acad Sci USA. 2004;101(31):11209–11214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Legro RS, Kunselman AR, Miller SA, Satyaswaroop PG. Role of androgens in the growth of endometrial carcinoma: an in vivo animal model. Am J Obstet Gynecol. 2001;184(3):303–308.

    Article  CAS  PubMed  Google Scholar 

  13. Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumour Biol. 2011;32(3):451–459.

    Article  CAS  PubMed  Google Scholar 

  14. Rodriguez G, Bilbao C, Ramirez R, et al. Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. Int J Cancer. 2006;118(6):1420–1425.

    Article  CAS  PubMed  Google Scholar 

  15. Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest. 2006;62(4):226–228.

    Article  PubMed  Google Scholar 

  16. Johnson SM, Maleki-Dizaji M, Styles JA, White IN. Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen. Endocr Relat Cancer. 2007;14(2):337–350.

    Article  CAS  PubMed  Google Scholar 

  17. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactiva-tors: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA. 1999;96(10):5458–5463.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ma WL, Hsu CL, Yeh CC, et al. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology. 2012;56(1):176–185.

    Article  CAS  PubMed  Google Scholar 

  19. Petriz J. Flow cytometry of the side population (SP). Curr Protoc Cytom. 2007;Chapter 9:Unit9.23.

    Google Scholar 

  20. Li H, Qi Y, Li C, et al. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther. 2009;8(12):3255–3265.

    Article  CAS  PubMed  Google Scholar 

  21. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994;54(11):3049–3053.

    CAS  PubMed  Google Scholar 

  22. Honig A, Weidler C, Hausler S, et al. Overexpression of poly-comb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res. 2010;30(5):1559–1564.

    CAS  PubMed  Google Scholar 

  23. Hubbard SA, Friel AM, Kumar B, Zhang L, Rueda BR, Gargett CE. Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res. 2009;69(21):8241–8248.

    Article  CAS  PubMed  Google Scholar 

  24. Mak VC, Siu MK, Wong OG, Chan KK, Ngan HY, Cheung AN. Dysregulated sternness-related genes in gynecological malignancies. Histol Histopathol. 2012;27(9):1121–1130.

    CAS  PubMed  Google Scholar 

  25. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Haupt-mann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002;161(4):1215–1221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hubbard SA, Gargett CE. A cancer stem cell origin for human endometrial carcinoma? Reproduction. 2010;140(1):23–32.

    Article  CAS  PubMed  Google Scholar 

  27. Lakhani NJ, Venitz J, Figg WD, Sparreboom A. Pharmacogenetics of estrogen metabolism and transport in relation to cancer. Curr Drug Metab. 2003;4(6):505–513.

    Article  CAS  PubMed  Google Scholar 

  28. Kishaba Y, Matsubara D, Niki T. Heterogeneous expression of nestin in myofibroblasts of various human tissues. Pathol Int. 2010;60(5):378–385.

    Article  PubMed  Google Scholar 

  29. Li Z, Hu S, Wang J, et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol. 2010;119(1):125–130.

    Article  CAS  PubMed  Google Scholar 

  30. Fukunaga-Kalabis M, Martinez G, Nguyen TK, et al. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene. 2010;29(46):6115–6124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. McAuliffe SM, Morgan SL, Wyant GA, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA. 2012;109(43): E2939–E2948.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ma WL, Hsu CL, Wu MH, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008;135(3):947–955, 955.e941–955.e945.

    Article  CAS  PubMed  Google Scholar 

  33. Ferretti V, Poitras C, Bergeron D, Coulombe B, Robert F, Blanchette M. PReMod: a database of genome-wide mammalian cis-regulatory module predictions. Nucleic Acids Res. 2007; 35(Database issue):D122–D126.

    Google Scholar 

  34. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):226–233.

    Article  CAS  PubMed  Google Scholar 

  35. Kyo S, Maida Y, Inoue M. Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions. Cancer Lett. 2011;308(2):123–133.

    Article  CAS  PubMed  Google Scholar 

  36. Bonkhoff H, Remberger K. Differentiation pathways and histoge-netic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate. 1996;28(2):98–106.

    Article  CAS  PubMed  Google Scholar 

  37. Barclay WW, Axanova LS, Chen W, et al. Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells. 2008;26(3):600–610.

    Article  CAS  PubMed  Google Scholar 

  38. Lee SO, Ma Z, Yeh CR, et al. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol. 2013;5(1):14–26.

    Article  CAS  PubMed  Google Scholar 

  39. Xin L, Lukacs RU, Lawson DA, Cheng D, Witte ON. Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells. 2007;25(11):2760–2769.

    Article  CAS  PubMed  Google Scholar 

  40. Abou-Kheir WG, Hynes PG, Martin PL, Pierce R, Kelly K. Characterizing the contribution of stem/progenitor cells to tumor-igenesis in the Pten-/-TP53-/- prostate cancer model. Stem Cells. 2010;28(12):2129–2140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Germann M, Wetterwald A, Guzman-Ramirez N, et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells. 2012;30(6):1076–1086.

    Article  CAS  PubMed  Google Scholar 

  42. Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON. Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012;72(18):4672–4681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Huang CK, Lee SO, Lai KP, et al. Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatology. 2013;57(4):1550–1563.

    Article  CAS  PubMed  Google Scholar 

  44. Sauter CN, McDermid RL, Weinberg AL, et al. Differentiation of murine embryonic stem cells induces progesterone receptor gene expression. Exp Cell Res. 2005;311(2):251–264.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipo-genesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003;144(11):5081–5088.

    Article  CAS  PubMed  Google Scholar 

  46. Chang CY, Hsuuw YD, Huang FJ, et al. Androgenic and antian-drogenic effects and expression of androgen receptor in mouse embryonic stem cells. Fertil Steril. 2006;85(suppl 1):1195–1203.

    Article  CAS  PubMed  Google Scholar 

  47. Claustres M, Sultan C. Stimulatory effects of androgens on normal children’s bone marrow in culture: effects on BFU-E, CFU-E, and uroporphyrinogen I synthase activity. Horm Res. 1986;23(2):91–98.

    Article  CAS  PubMed  Google Scholar 

  48. Sullivan PS, Jackson CW, McDonald TP. Castration decreases thrombocytopoiesis and testosterone restores platelet production in castrated BALB/c mice: evidence that testosterone acts on a bipotential hematopoietic precursor cell. J Lab Clin Med. 1995;125(3):326–333.

    CAS  PubMed  Google Scholar 

  49. Viselli SM, Reese KR, Fan J, Kovacs WJ, Olsen NJ. Androgens alter B cell development in normal male mice. Cell Immunol. 1997;182(2):99–104.

    Article  CAS  PubMed  Google Scholar 

  50. Erben RG, Eberle J, Stangassinger M. B lymphopoiesis is upregu-lated after orchiectomy and is correlated with estradiol but not testosterone serum levels in aged male rats. Horm Metab Res. 2001;33(8):491–498.

    Article  CAS  PubMed  Google Scholar 

  51. Brannvall K, Bogdanovic N, Korhonen L, Lindholm D. 19-Nortestosterone influences neural stem cell proliferation and neurogenesis in the rat brain. Eur J Neurosci. 2005;21(4):871–878.

    Article  PubMed  Google Scholar 

  52. Yang HP, Garcia-Closas M, Lacey JV Jr, et al. Genetic variation in the androgen receptor gene and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18(2):585–589.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ju W, Kim SC. Polymorphisms in CAG active allele length of the androgen receptor gene are not associated with increased risk of endometrial cancer. Cancer Genet Cytogenet. 2007;172(2):178–179.

    Article  CAS  PubMed  Google Scholar 

  54. Pignata S, Scambia G, Pisano C, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96(11):1639–1643.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006;58(3):242–256.

    Article  PubMed  Google Scholar 

  56. Egawa-Takata T, Ueda Y, Kuragaki C, et al. Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy. Cancer Chemother Pharmacol. 2011;68(6):1603–1610.

    Article  CAS  PubMed  Google Scholar 

  57. Horie K, Takakura K, Imai K, Liao S, Mori T. Immunohistochem-ical localization of androgen receptor in the human endometrium, decidua, placenta and pathological conditions of the endometrium. Hum Reprod. 1992;7(10):1461–1466.

    Article  CAS  PubMed  Google Scholar 

  58. Fujimoto J, Nishigaki M, Hori M, Ichigo S, Itoh T, Tamaya T. The effect of estrogen and androgen on androgen receptors and mRNA levels in uterine leiomyoma, myometrium and endometrium of human subjects. J Steroid Biochem Mol Biol. 1994;50(3–4): 137–143.

    Article  Google Scholar 

  59. Minorics R, Bozsity N, Wolfling J, et al. Antiproliferative effect of normal and 13-epi-D-homoestrone and their 3-methyl ethers on human reproductive cancer cell lines. J Steroid Biochem Mol Biol. 2012;132(1–2):168–175.

    Article  CAS  PubMed  Google Scholar 

  60. Chon HS, Marchion DC, Xiong Y, et al. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 2012;124(1):119–124.

    Article  CAS  PubMed  Google Scholar 

  61. Chen H, Libertini SJ, George M, et al. Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer. 2010;17(4):857–873.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Moutsatsou P, Sekeris CE. Steroid receptors in the uterus: implications in endometriosis. Ann N YAcad Sci. 2003;997:209–222.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of OB/GYN, China Medical University Hospital, Taichung, Taiwan

    Lumin Chen MD, Wei-Chun Chang MD, Yao-Ching Hung MD, PhD, Ying-Yi Chang MD, Bo-Yin Bao PhD, Hsin-Ching Huang MS, Wei-Min Chung MS, Chih-Rong Shyr PhD & Wen-Lung Ma PhD

  2. Department of Pharmacology, China Medical University, Taichung, Taiwan

    Bo-Yin Bao PhD

  3. Sex Hormone Research Center, Graduate Institution of Clinical Medical Science, School of Medicine, China Medical University Hospital, 505 Rm, 6 Xueshi Rd, North District, Taichung City, 404, Taiwan

    Lumin Chen MD, Yao-Ching Hung MD, PhD, Wei-Min Chung MS, Chih-Rong Shyr PhD & Wen-Lung Ma PhD

Authors
  1. Lumin Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei-Chun Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yao-Ching Hung MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying-Yi Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bo-Yin Bao PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hsin-Ching Huang MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei-Min Chung MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chih-Rong Shyr PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wen-Lung Ma PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen-Lung Ma PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, L., Chang, WC., Hung, YC. et al. Androgen Receptor Increases CD133 Expression and Progenitor-Like Population That Associate With Cisplatin Resistance in Endometrial Cancer Cell Line. Reprod. Sci. 21, 386–394 (2014). https://doi.org/10.1177/1933719113497281

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1933719113497281

Keywords

Search

Navigation